Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Cardiovasc Electrophysiol ; 32(8): 2238-2245, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34165227

RESUMO

PURPOSE: We sought to study the predictive value of the metabolic heterogeneous zone (HZ) as determined by 18 Fluorodeoxyglucose (18 FDG) positron emission tomography (PET) viability studies in ventricular tachycardia (VT) patients. METHODS: PET studies utilizing 82 Rubidium (82 Rb) tracer for perfusion and 18 FDG tracer for viability were analyzed using PMOD (PMOD Technologies) and further analyzed using 684-segment plots. 18 FDG uptake was normalized to the area with maximal perfusion on the rest 82 Rb study. Metabolic scar, HZ, and healthy segments were defined with perfusion-normalized 18 FDG uptake between 0%-50%, 50%-70%, and >70%, respectively. RESULTS: Thirty-four VT patients (age, 63 ± 12 years) were evaluated with 18 FDG-PET viability study. Most (n = 31) patients underwent VT ablation. Patients were categorized to HZ < median versus HZ ≥ median based on a median HZ area size of 21.0 cm2 . HZ size was significantly larger in the deceased group than the alive group (35.2 cm2 vs. 18.1 cm2 , p = .01). Deaths were significantly higher in HZ ≥ 21 cm2 group than HZ < 21 cm2 group (58.8% vs. 11.8%, p = .005). Survival analysis showed significantly higher mortality in the HZ ≥ 21 cm2 group than the HZ < 21 cm2 group (HR = 4.1, 95% CI: 1.3-12.6, p = .016). In a multivariable analysis, HZ was found to be an independent predictor for all-cause mortality (HR = 1.07, 95% CI: 1.02-1.12, p = .01) CONCLUSIONS: Increased HZ size of myocardium was associated with increased mortality. Metabolic HZ quantification may be of value in risk stratification and management of ischemic and nonischemic patients with VT.


Assuntos
Fluordesoxiglucose F18 , Taquicardia Ventricular , Idoso , Cicatriz/patologia , Humanos , Pessoa de Meia-Idade , Miocárdio/patologia , Tomografia por Emissão de Pósitrons , Taquicardia Ventricular/diagnóstico por imagem , Taquicardia Ventricular/patologia , Taquicardia Ventricular/cirurgia
3.
JACC Clin Electrophysiol ; 9(8 Pt 3): 1719-1729, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37227359

RESUMO

BACKGROUND: Multiple cardiac sarcoidosis (CS) diagnostic schemes have been published. OBJECTIVES: This study aims to evaluate the association of different CS diagnostic schemes with adverse outcomes. The diagnostic schemes evaluated were 1993, 2006, and 2017 Japanese criteria and the 2014 Heart Rhythm Society criteria. METHODS: Data were collected from the Cardiac Sarcoidosis Consortium, an international registry of CS patients. Outcome events were any of the following: all-cause mortality, left ventricular assist device placement, heart transplantation, and appropriate implantable cardioverter-defibrillator therapy. Logistic regression analysis evaluated the association of outcomes with each CS diagnostic scheme. RESULTS: A total of 587 subjects met the following criteria: 1993 Japanese (n = 310, 52.8%), 2006 Japanese (n = 312, 53.2%), 2014 Heart Rhythm Society (n = 480, 81.8%), and 2017 Japanese (n = 112, 19.1%). Patients who met the 1993 criteria were more likely to experience an event than patients who did not (n = 109 of 310, 35.2% vs n = 59 of 277, 21.3%; OR: 2.00; 95% CI: 1.38-2.90; P < 0.001). Similarly, patients who met the 2006 criteria were more likely to have an event than patients who did not (n = 116 of 312, 37.2% vs n = 52 of 275, 18.9%; OR: 2.54; 95% CI: 1.74-3.71; P < 0.001). There was no statistically significant association between the occurrence of an event and whether a patient met the 2014 or the 2017 criteria (OR: 1.39; 95% CI: 0.85-2.27; P = 0.18 or OR: 1.51; 95% CI: 0.97-2.33; P = 0.067, respectively). CONCLUSIONS: CS patients who met the 1993 and the 2006 criteria had higher odds of adverse clinical outcomes. Future research is needed to prospectively evaluate existing diagnostic schemes and develop new risk models for this complex disease.


Assuntos
Cardiomiopatias , Desfibriladores Implantáveis , Transplante de Coração , Miocardite , Sarcoidose , Humanos , Sarcoidose/diagnóstico , Sarcoidose/epidemiologia , Sarcoidose/complicações , Desfibriladores Implantáveis/efeitos adversos
4.
Resuscitation ; 181: 140-146, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36410605

RESUMO

INTRODUCTION: Transcutaneous cardiac pacing (TCP) is a lifesaving procedure for patients with certain types of unstable bradycardia. We aimed to assess the difference in the pacing thresholds between the anteroposterior (AP) and anterolateral (AL) pacer pad positions. The second aim was to characterize the severity of chest wall muscle contractions during TCP. METHODS: In this prospective crossover trial, we enrolled patients presenting to the electrophysiology laboratory for elective cardioversion. After successful cardioversion, sedated participants were sequentially paced in both positions. The study procedure concluded after successful capture or inability to achieve capture by 140 mA (the pacer's maximum output) in both positions. Pacing thresholds were compared between positions, using a student's paired t-test, assigning a value of 141 mA to any trials with non-capture. RESULTS: Forty-one patients were screened; 20 were enrolled in the study. Seven participants were excluded from the paired analysis (three were prevented from pacing in the second position at the anesthesiologist's discretion, and 4 did not capture in either position). The study population consisted of 14 men and 6 women with a median age of 65 years. The mean pacing threshold was 33 mA lower (P = 0.001, 95% CI 20-45) in the AP (93 mA) versus the AL (126 mA) position. The median contraction severity score was 3 in the AL position versus 4 in the AP position (P = 0.005). CONCLUSIONS: Placing pacer pads in the AP position requires less energy to capture. Major resuscitation guidelines may favor the AP position for TCP. CLINICALTRIALS: gov Identifier: NCT03898050 https://clinicaltrials.gov/ct2/show/NCT03898050.


Assuntos
Bradicardia , Estimulação Cardíaca Artificial , Idoso , Feminino , Humanos , Masculino , Bradicardia/terapia , Estimulação Cardíaca Artificial/métodos , Cardioversão Elétrica , Coração , Estudos Prospectivos , Estudos Cross-Over
5.
IEEE Robot Autom Lett ; 3(4): 4038-4045, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30923746

RESUMO

To treat atrial fibrillation (AFib), radiofrequency ablation is usually implemented with a cardiac catheter to block abnormal electrical signals from pulmonary veins. However, it is challenging to manipulate a passive catheter. In addition, the radiation exposure to patients under fluoroscopic guidance has been a concern. To address these two major issues, this work presents the development of a steerable and MRI-compatible cardiac catheter by using shape memory alloy (SMA) as an alternative interventional tool for AFib. The developed cardiac catheter is comprised of a passive and flexible tubing and a steerable tip. The tip is composed of multiple bending modules and each module is actuated by a pair of antagonistic SMA wires. To improve the MRI-compatibility of SMA actuators, the electric current required for SMA actuation is significantly reduced by developing a technique of conductive heating actuation. In this paper, the design and fabrication of the cardiac catheter are presented, followed by modeling the SMA bending module. The working performance of the SMA bending module is experimentally studied. In the end, a proof-of-concept demonstration of the cardiac catheter is performed in an explanted heart.

7.
Heart Rhythm ; 14(10): e495-e500, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-28965612

RESUMO

The Heart Rhythm Society (HRS) has been developing clinical practice documents in collaboration and partnership with other professional medical societies since 1996. The HRS formed a Scientific and Clinical Documents Committee (SCDC) with the sole purpose of managing the development of these documents from conception through publication. The SCDC oversees the process for developing clinical practice documents, with input and approval from the HRS Executive Committee and the Board of Trustees. As of May 2017, the HRS has produced more than 80 publications with other professional organizations. This process manual is produced to publicly and transparently declare the standards by which the HRS develops clinical practice documents, which include clinical practice guidelines, expert consensus statements, scientific statements, clinical competency statements, task force policy statements, and proceedings statements. The foundation for this process is informed by the Institute of Medicine's standards for developing trustworthy clinical practice guidelines; the new criteria from the National Guidelines Clearinghouse, effective June 2014; SCDC member discussions; and a review of guideline policies and methodologies used by other professional organizations.


Assuntos
Arritmias Cardíacas/terapia , Cardiologia/organização & administração , Consenso , Formulação de Políticas , Sociedades Médicas , Humanos , Estados Unidos
8.
J Am Coll Cardiol ; 67(6): 674-683, 2016 Feb 16.
Artigo em Inglês | MEDLINE | ID: mdl-26868693

RESUMO

BACKGROUND: Radiofrequency catheter ablation is used to treat recurrent ventricular tachycardia (VT). OBJECTIVES: This study evaluated long-term safety and effectiveness of radiofrequency catheter ablation using an open-irrigated catheter. METHODS: Patients with sustained monomorphic ventricular tachycardia associated with coronary disease were analyzed for cardiovascular-specific adverse events within 7 days of treatment, hospitalization duration, 6-month sustained monomorphic ventricular tachycardia recurrence, quality of life measured by the Hospital Anxiety and Depression Scale, long-term (1-, 2-, and 3-year) survival, symptomatic VT control, and amiodarone use. RESULTS: Overall, 249 patients, mean age 67.4 years, were enrolled. The cardiovascular-specific adverse events rate was 3.9% (9 of 233) with no strokes. Noninducibility of targeted VT was achieved in 75.9% of patients. Post-ablation median hospitalization was 2 days. At 6 months, 62.0% (114 of 184) of patients had no sustained monomorphic ventricular tachycardia recurrence; the proportion of patients with implantable cardioverter-defibrillator shocks decreased from 81.2% to 26.8% (p < 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with recurrences was reduced by ≥50% in 63.8% of patients; and the proportion with normal Hospital Anxiety and Depression Scale scores increased from 48.8% to 69.1% (p < 0.001). Patient-reported VT remained steady for 1, 2, and 3 years at 22.7%, 29.8%, and 24.1%, respectively. Amiodarone use and hospitalization decreased from 55% and 77.2% pre-ablation to 23.3% and 30.7%, 18.5% and 36.7%, 17.7% and 31.3% at 1, 2, and 3 years, respectively. CONCLUSIONS: Radiofrequency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT episodes and improved quality of life at 6 months. A steady 3-year nonrecurrence rate with reduced amiodarone use and hospitalizations indicate improved long-term outcomes. (NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia [THERMOCOOL VT]; NCT00412607).


Assuntos
Ablação por Cateter/métodos , Frequência Cardíaca/fisiologia , Taquicardia Ventricular/cirurgia , Adulto , Idoso , Idoso de 80 Anos ou mais , Ablação por Cateter/instrumentação , Aprovação de Equipamentos , Desenho de Equipamento , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade de Vida , Recidiva , Estudos Retrospectivos , Taquicardia Ventricular/fisiopatologia , Irrigação Terapêutica/métodos , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA